PDCD1 and ovarian carcinoma: Our findings showed an actionable way to reverse the immunosuppression of highly expressed PS1 in CAFs by blocking PS1 to improve CTL trafficking and migration and therefore improve the therapeutic outcome in different types of cancers, including ovarian cancer, either independently or in combination with immune checkpoint inhibitors such as PD-1 or PD-L1 blockers.